P. Bakakos, E. Fouka, P. Galanakis, K. Katsoulis, K. Kostikas, S. Loukides, N. Mathioudakis, Konstantinos Porpodis, K. Samitas, P. Steiropoulos, E. Zervas
Type 2 (T2)-low severe asthma (SA) presents a distinct subpopulation for which, in lack of a consistent classification system, epidemiological and clinical outcome data remain unclear and therapeutic needs remain largely unmet. The aim of the PHOLLOW real-world study is to assess the prevalence and predictors of T2-low SA, and depict the patient profile, clinical features, treatment patterns and disease burden using clinical and patient-reported outcomes (PROs) in routine settings in Greece. This is a cross-sectional and retrospective chart review 2-part study that will enroll 600 adult outpatients with SA over a 1-year period by 20–30 asthma specialists. A new SA phenotype classification system and two different definitions proposed herein will be used to categorize patients into definite or possible T2-low (unlikely or least likely T2-high) SA, and definite/most likely or possible/likely T2-high SA, based on a composite measure of airway inflammation markers (blood eosinophil counts, fractional exhaled nitric oxide), allergic/atopic status and age-of-onset phenotype, taking into consideration the current receipt of biologic and/or maintenance oral corticosteroid treatment and response to it. Part A will collect top-level data for all participants to assess T2-low SA prevalence and predictors. T2-low SA patients will proceed to part B, where further data and PROs assessing asthma symptom control, quality of life, anxiety, depression, work productivity and activity impairment will be collected.
{"title":"Protocol, rationale and design of the PHOLLOW\u0000cross-sectional and retrospective chart review\u0000study to assess the prevalence and characterize the\u0000patient profile, clinical features and disease burden\u0000of type-2 low severe asthma in routine care settings\u0000in Greece","authors":"P. Bakakos, E. Fouka, P. Galanakis, K. Katsoulis, K. Kostikas, S. Loukides, N. Mathioudakis, Konstantinos Porpodis, K. Samitas, P. Steiropoulos, E. Zervas","doi":"10.18332/pne/157014","DOIUrl":"https://doi.org/10.18332/pne/157014","url":null,"abstract":"Type 2 (T2)-low severe asthma (SA) presents a distinct subpopulation for which, in lack of a consistent classification system, epidemiological and clinical outcome data remain unclear and therapeutic needs remain largely unmet. The aim of the PHOLLOW real-world study is to assess the prevalence and predictors of T2-low SA, and depict the patient profile, clinical features, treatment patterns and disease burden using clinical and patient-reported outcomes (PROs) in routine settings in Greece. This is a cross-sectional and retrospective chart review 2-part study that will enroll 600 adult outpatients with SA over a 1-year period by 20–30 asthma specialists. A new SA phenotype classification system and two different definitions proposed herein will be used to categorize patients into definite or possible T2-low (unlikely or least likely T2-high) SA, and definite/most likely or possible/likely T2-high SA, based on a composite measure of airway inflammation markers (blood eosinophil counts, fractional exhaled nitric oxide), allergic/atopic status and age-of-onset phenotype, taking into consideration the current receipt of biologic and/or maintenance oral corticosteroid treatment and response to it. Part A will collect top-level data for all participants to assess T2-low SA prevalence and predictors. T2-low SA patients will proceed to part B, where further data and PROs assessing asthma symptom control, quality of life, anxiety, depression, work productivity and activity impairment will be collected.","PeriodicalId":42353,"journal":{"name":"Pneumon","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90484706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The effects of the climate crisis have been well established with the first global efforts to address the issue made over 30 years ago. The global healthcare sector is a large contributor to the total greenhouse gas (GHG) emissions, with the recent focus on the respiratory care sector. However, recent directives to address these emissions include ‘blanket unconsented switching’ of stable respiratory patients from pressurized metered dose inhalers (pMDIs) to dry powder inhalers (DPIs), which has the potential to cause a multitude of serious consequences for the patient. This article reviews the broad consequences and provides recommendations to encourage an environmentally friendly patient-centered approach without causing harm to the patient
{"title":"Inhalers and the Environment: Pollution, Plastics and Policy","authors":"Monbi Chakma, O. Usmani","doi":"10.18332/pne/154608","DOIUrl":"https://doi.org/10.18332/pne/154608","url":null,"abstract":"The effects of the climate crisis have been well established with the first global efforts to address the issue made over 30 years ago. The global healthcare sector is a large contributor to the total greenhouse gas (GHG) emissions, with the recent focus on the respiratory care sector. However, recent directives to address these emissions include ‘blanket unconsented switching’ of stable respiratory patients from pressurized metered dose inhalers (pMDIs) to dry powder inhalers (DPIs), which has the potential to cause a multitude of serious consequences for the patient. This article reviews the broad consequences and provides recommendations to encourage an environmentally friendly patient-centered approach without causing harm to the patient","PeriodicalId":42353,"journal":{"name":"Pneumon","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87629249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michaella Alexandrou, S. Daskalopoulou, Anna-Louiza Haliassou, E. Kranidioti, E. Margellou, A. Panagopoulos, E. Papageorgiou, Artemis Rodopoulou, G. Stavropoulou, Apostolos G. Pappas, I. Kalomenidis
K. Kostikas, P. Bakakos, Petros A. Galanakis, G. Hillas, G. Konstantinou, M. Makris, N. Mathioudakis, Konstantinos Porpodis, N. Rovina, E. Zervas, S. Loukides
Severe eosinophilic asthma (SEA) is associated with poor disease control and compromised health-related quality of life (HRQoL), leading to a substantial psychosocial and economic disease burden. Benralizumab, an interleukin-5-alpha receptor monoclonal antibody, is approved as an add-on maintenance treatment for SEA, yet real-world evidence of its effectiveness is limited. EMPOWAIR is a non-interventional, multicenter, 48-week prospective cohort study aiming to evaluate the clinical effectiveness and the patient-perceived impact of benralizumab on HRQoL, sleep quality, depression, anxiety, work productivity and activity impairment among SEA patients treated in routine care settings in Greece. The study will also engage advanced remote patient monitoring technologies using portable spirometers and wearable activity trackers to collect data on lung function parameters and physical activity. The study plans to consecutively enroll 150 adult patients treated by lung specialists practicing in various healthcare settings across the country over an 18-month recruitment Eligible patients must be newly prescribed benralizumab per the approved label. Primary data will be collected at enrollment and 4, 16, 32, and 48 weeks after initiation through routine clinic or as the standard clinical assess the change from baseline in HRQoL, as measured by the St. George’s Respiratory Questionnaire (SGRQ), and to estimate the proportion of patients achieving a minimum clinically important improvement in respiratory health status, defined as ≥ 4-point reduction from baseline in SGRQ total score, after 16 weeks of benralizumab treatment. The study rationale, design and protocol, are described herein.
{"title":"Capturing patient-centered outcomes using innovative technologies in adults with severe eosinophilic asthma on benralizumab: Τhe EMPOWAIR real-world study design","authors":"K. Kostikas, P. Bakakos, Petros A. Galanakis, G. Hillas, G. Konstantinou, M. Makris, N. Mathioudakis, Konstantinos Porpodis, N. Rovina, E. Zervas, S. Loukides","doi":"10.18332/pne/154605","DOIUrl":"https://doi.org/10.18332/pne/154605","url":null,"abstract":"Severe eosinophilic asthma (SEA) is associated with poor disease control and compromised health-related quality of life (HRQoL), leading to a substantial psychosocial and economic disease burden. Benralizumab, an interleukin-5-alpha receptor monoclonal antibody, is approved as an add-on maintenance treatment for SEA, yet real-world evidence of its effectiveness is limited. EMPOWAIR is a non-interventional, multicenter, 48-week prospective cohort study aiming to evaluate the clinical effectiveness and the patient-perceived impact of benralizumab on HRQoL, sleep quality, depression, anxiety, work productivity and activity impairment among SEA patients treated in routine care settings in Greece. The study will also engage advanced remote patient monitoring technologies using portable spirometers and wearable activity trackers to collect data on lung function parameters and physical activity. The study plans to consecutively enroll 150 adult patients treated by lung specialists practicing in various healthcare settings across the country over an 18-month recruitment Eligible patients must be newly prescribed benralizumab per the approved label. Primary data will be collected at enrollment and 4, 16, 32, and 48 weeks after initiation through routine clinic or as the standard clinical assess the change from baseline in HRQoL, as measured by the St. George’s Respiratory Questionnaire (SGRQ), and to estimate the proportion of patients achieving a minimum clinically important improvement in respiratory health status, defined as ≥ 4-point reduction from baseline in SGRQ total score, after 16 weeks of benralizumab treatment. The study rationale, design and protocol, are described herein.","PeriodicalId":42353,"journal":{"name":"Pneumon","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80479196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Stylianos Vittorakis *, Vasiliki Georgakopoulou *, G. Apollonatos, S. Loukides, A. Liapikou
INTRODUCTION The COVID-19 pandemic has overwhelmed the capacities of healthcare systems. Primary care physicians had a pivotal role in reducing the unnecessary access of suspected and confirmed cases to hospitals, and they substantially contributed to the success of vaccination programs. In this study, we aim to determine the role of the Greek private primary care pulmonologists (PPCPs) network during the first year of the pandemic. METHODS An electronic questionnaire consisting of 28 simple questions was administered to PPCPs by e-mail or by sharing a link in private social networking groups. RESULTS A total of 150 PPCPs completed the study. According to their answers, they examined a significant portion of suspected and confirmed COVID-19 cases, and they offered to several patients blood testing and chest radiography. PPCPS maintained close contact with both patients that had faceto-face assessment and patients managed remotely with a great number of telephone contacts. The majority of PPCPs provided information for COVID-19 vaccination by telephone for more than 20 patients weekly. CONCLUSIONS PPCPs offered high quality and specialized support for COVID-19 patients. Besides, they supported the national vaccination program by informing a substantial number of patients.
{"title":"The role of private primary care pulmonologists network in Greece in the first year of COVID-19 pandemic","authors":"Stylianos Vittorakis *, Vasiliki Georgakopoulou *, G. Apollonatos, S. Loukides, A. Liapikou","doi":"10.18332/pne/153021","DOIUrl":"https://doi.org/10.18332/pne/153021","url":null,"abstract":"INTRODUCTION The COVID-19 pandemic has overwhelmed the capacities of healthcare systems. Primary care physicians had a pivotal role in reducing the unnecessary access of suspected and confirmed cases to hospitals, and they substantially contributed to the success of vaccination programs. In this study, we aim to determine the role of the Greek private primary care pulmonologists (PPCPs) network during the first year of the pandemic. METHODS An electronic questionnaire consisting of 28 simple questions was administered to PPCPs by e-mail or by sharing a link in private social networking groups. RESULTS A total of 150 PPCPs completed the study. According to their answers, they examined a significant portion of suspected and confirmed COVID-19 cases, and they offered to several patients blood testing and chest radiography. PPCPS maintained close contact with both patients that had faceto-face assessment and patients managed remotely with a great number of telephone contacts. The majority of PPCPs provided information for COVID-19 vaccination by telephone for more than 20 patients weekly. CONCLUSIONS PPCPs offered high quality and specialized support for COVID-19 patients. Besides, they supported the national vaccination program by informing a substantial number of patients.","PeriodicalId":42353,"journal":{"name":"Pneumon","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90886013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dimitrios Molyvas, M. Kipourou, S. Lampridis, K. Kipourou, P. Koutoukoglou, I. Tsanaktsidis, G. Spyropoulos, K. Katsoulis
A chest computed tomography (chest CT) revealed diffuse ground glass infiltrates in the apical and posterior segments of the right upper lobe and alveolar infiltrates in the remainder of the lungs, findings compatible with diffuse alveolar hemorrhage (images could not be retrieved due to technical reasons). Recent bleeding originating from the right bronchial tree was the finding of ABSTRACT Massive hemoptysis is a life-threatening medical condition which usually occurs in the course of parenchymal destructive diseases. We herein report the case of a 61-year-old male patient who presented with massive hemoptysis six months after commencement of dual antiplatelet therapy with acetylsalicylic acid and ticagrelor, for drug-eluting coronary stents. Control of bleeding with discontinuation of both antiplatelet agents, as well as negative imaging and laboratory studies for other pulmonary hemorrhage causes, indicate that either of the antiplatelet drugs or combination thereof was the cause of the pulmonary hemorrhage. In contrast to the previous limited case reports with pulmonary hemorrhage early during antiplatelet therapy with ticagrelor, this case highlights that it can even occur later in the course of antiplatelet therapy.
{"title":"A life-threatening massive hemoptysis case in the course of dual antiplatelet therapy with ticagrelor","authors":"Dimitrios Molyvas, M. Kipourou, S. Lampridis, K. Kipourou, P. Koutoukoglou, I. Tsanaktsidis, G. Spyropoulos, K. Katsoulis","doi":"10.18332/pne/152774","DOIUrl":"https://doi.org/10.18332/pne/152774","url":null,"abstract":"A chest computed tomography (chest CT) revealed diffuse ground glass infiltrates in the apical and posterior segments of the right upper lobe and alveolar infiltrates in the remainder of the lungs, findings compatible with diffuse alveolar hemorrhage (images could not be retrieved due to technical reasons). Recent bleeding originating from the right bronchial tree was the finding of ABSTRACT Massive hemoptysis is a life-threatening medical condition which usually occurs in the course of parenchymal destructive diseases. We herein report the case of a 61-year-old male patient who presented with massive hemoptysis six months after commencement of dual antiplatelet therapy with acetylsalicylic acid and ticagrelor, for drug-eluting coronary stents. Control of bleeding with discontinuation of both antiplatelet agents, as well as negative imaging and laboratory studies for other pulmonary hemorrhage causes, indicate that either of the antiplatelet drugs or combination thereof was the cause of the pulmonary hemorrhage. In contrast to the previous limited case reports with pulmonary hemorrhage early during antiplatelet therapy with ticagrelor, this case highlights that it can even occur later in the course of antiplatelet therapy.","PeriodicalId":42353,"journal":{"name":"Pneumon","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89253853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S. Bashirian, Hossein Effatpanah, M. Barati, Salman Khazaee, A. Farhadinasab, Mojdeh Shokri, A. Poormohammadi, E. Ezati
INTRODUCTION In recent decades, hookah use has been considered a common method of smoking. Since hookah use is one of the factors exacerbating the coronavirus disease, COVID-19, the present study aimed to determine the factors affecting hookah smoking during the COVID-19 pandemic using protection motivation theory (PMT). METHODS This is a cross-sectional study and conducted on 560 people aged ≥13 years living in Hamedan. Data were collected electronically using a researcher-made questionnaire consisting of three parts. The first, second, and third parts included demographic information, questions about hookah use, and information about the constructs of PMT, respectively. Data were analyzed using SPSS 22 software. RESULTS The mean age of the participants was 28.8 ± 9.6 years. In the regression analysis of perceived reward structures (β=0.378), perception sensitivity (β=0.208), self-efficacy (β=0.0166) were respectively the important predictors for the intention of hookah use behavior. Overall, the constructs of the PMT explain 71% of the variance of the changes in the behavioral intention construct in the participants. No significant relationship was observed between self-efficacy constructs (r=0.039) and perceived cost. The prevalence of hookah use before the COVID-19 pandemic in participants was 41.8%, which decreased to 35% during the COVID-19 pandemic. CONCLUSIONS A greater correlation between the constructs of the PMT concerning protective behaviors against COVID-19 emphasizes designing educational programs based on this theory and the role of media to increase people’s knowledge in preventive behaviors.
{"title":"Investigating the factors affecting hookah smoking during the COVID-19 pandemic: Application of Protection Motivation Theory","authors":"S. Bashirian, Hossein Effatpanah, M. Barati, Salman Khazaee, A. Farhadinasab, Mojdeh Shokri, A. Poormohammadi, E. Ezati","doi":"10.18332/pne/147970","DOIUrl":"https://doi.org/10.18332/pne/147970","url":null,"abstract":"INTRODUCTION In recent decades, hookah use has been considered a common method of smoking. Since hookah use is one of the factors exacerbating the coronavirus disease, COVID-19, the present study aimed to determine the factors affecting hookah smoking during the COVID-19 pandemic using protection motivation theory (PMT). METHODS This is a cross-sectional study and conducted on 560 people aged ≥13 years living in Hamedan. Data were collected electronically using a researcher-made questionnaire consisting of three parts. The first, second, and third parts included demographic information, questions about hookah use, and information about the constructs of PMT, respectively. Data were analyzed using SPSS 22 software. RESULTS The mean age of the participants was 28.8 ± 9.6 years. In the regression analysis of perceived reward structures (β=0.378), perception sensitivity (β=0.208), self-efficacy (β=0.0166) were respectively the important predictors for the intention of hookah use behavior. Overall, the constructs of the PMT explain 71% of the variance of the changes in the behavioral intention construct in the participants. No significant relationship was observed between self-efficacy constructs (r=0.039) and perceived cost. The prevalence of hookah use before the COVID-19 pandemic in participants was 41.8%, which decreased to 35% during the COVID-19 pandemic. CONCLUSIONS A greater correlation between the constructs of the PMT concerning protective behaviors against COVID-19 emphasizes designing educational programs based on this theory and the role of media to increase people’s knowledge in preventive behaviors.","PeriodicalId":42353,"journal":{"name":"Pneumon","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78401998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A known complication associated with scleroderma or systemic sclerosis (SSc) is the development of interstitial lung disease (ILD). It is occasional that symptoms of connective tissue diseases (CTDs) emerge in patients with ILD that have previously ruled out rheumatologic etiology. Presented here is a unique case of scleroderma associated interstitial lung disease (SSc-ILD) where the diagnosis of scleroderma was made over 5 years after the diagnosis of ILD. A 52-year-old female presented with dyspnea on exertion and chronic cough with a history of ILD dating back 5 years. Initial consultation revealed negative autoimmune serology and no symptoms or signs associated with scleroderma. When new rheumatologic features presented months later, serology was repeated and showed positive antinuclear antibody with nucleolar pattern suggestive of scleroderma. This case shows a potential importance of thoroughly monitoring rheumatologic signs and symptoms with patients already diagnosed with ILD, even with no initial suggestions of CTDs.
{"title":"Atypical presentation and progression of scleroderma associated interstitial lung disease","authors":"Mackenzie Skov, S. Anees","doi":"10.18332/pne/149901","DOIUrl":"https://doi.org/10.18332/pne/149901","url":null,"abstract":"A known complication associated with scleroderma or systemic sclerosis (SSc) is the development of interstitial lung disease (ILD). It is occasional that symptoms of connective tissue diseases (CTDs) emerge in patients with ILD that have previously ruled out rheumatologic etiology. Presented here is a unique case of scleroderma associated interstitial lung disease (SSc-ILD) where the diagnosis of scleroderma was made over 5 years after the diagnosis of ILD. A 52-year-old female presented with dyspnea on exertion and chronic cough with a history of ILD dating back 5 years. Initial consultation revealed negative autoimmune serology and no symptoms or signs associated with scleroderma. When new rheumatologic features presented months later, serology was repeated and showed positive antinuclear antibody with nucleolar pattern suggestive of scleroderma. This case shows a potential importance of thoroughly monitoring rheumatologic signs and symptoms with patients already diagnosed with ILD, even with no initial suggestions of CTDs.","PeriodicalId":42353,"journal":{"name":"Pneumon","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88830337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Agathi Spyropoulou, Vassilis Spiropoulos, Georgia Spiropoulou, Christos Tsilivigos, K. Spiropoulos, N. Mastronikolis
{"title":"Surgical approaches in obstructive sleep apnea syndrome: A review of techniques","authors":"Agathi Spyropoulou, Vassilis Spiropoulos, Georgia Spiropoulou, Christos Tsilivigos, K. Spiropoulos, N. Mastronikolis","doi":"10.18332/pne/147971","DOIUrl":"https://doi.org/10.18332/pne/147971","url":null,"abstract":"","PeriodicalId":42353,"journal":{"name":"Pneumon","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74231043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Psathakis, Theofani Rimpa, Angeliki Kokkini-Paschou, J. Koutsikos
{"title":"Urinothorax: A pleural effusion that might not always\u0000be like urine","authors":"K. Psathakis, Theofani Rimpa, Angeliki Kokkini-Paschou, J. Koutsikos","doi":"10.18332/pne/148105","DOIUrl":"https://doi.org/10.18332/pne/148105","url":null,"abstract":"","PeriodicalId":42353,"journal":{"name":"Pneumon","volume":null,"pages":null},"PeriodicalIF":0.7,"publicationDate":"2022-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90680194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：